Treatment with the PPARδ agonist GW0742, through the targeting of the METRNL-E2F-PPARδ pathway, reduces the maximal respiratory capacity of METRNL, thereby inhibiting the growth of orthotopic gliomas in mice, as well as flank prostate and colorectal cancer [130]. Here, PPARD is linked to colorectal cancer.